[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631101":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":40,"centralContacts":44,"locations":55,"responsibleParty":71,"collaborators":49,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":49,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":104,"whyStopped":49,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral Dydrogesterone Group","EXPERIMENTAL","Participants will receive transdermal estradiol gel combined with oral dydrogesterone as the progesterone component of menopausal hormone therapy.",[13,14],"Drug: Dydrogesterone 10 MG Oral Tablet","Drug: Transdermal estradiol",{"label":16,"type":10,"description":17,"interventionNames":18},"Vaginal Micronized Progesterone Group","Participants will receive transdermal estradiol gel combined with vaginal micronized progesterone as the progesterone component of menopausal hormone therapy.",[19,14],"Drug: Micronized progesterone 200 MG",[21,28,34],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Dydrogesterone 10 MG Oral Tablet","Oral dydrogesterone will be administered in combination with transdermal estradiol as part of menopausal hormone therapy.",[9],[27],"Duphaston",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Micronized progesterone 200 MG","Vaginal micronized progesterone will be administered in combination with transdermal estradiol as part of menopausal hormone therapy.",[16],[33],"Progestan",{"type":22,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"Transdermal estradiol","Transdermal estradiol gel will be used as estrogen therapy in both treatment groups.",[9,16],[39],"Femijel",[41],{"name":42,"affiliation":5,"role":43},"Esra Ayanoglu","PRINCIPAL_INVESTIGATOR",[45,51],{"name":46,"role":47,"phone":48,"phoneExt":49,"email":50},"Esra Ayanoglu, MD","CONTACT","+90 544 544 62 42",null,"dresraayanoglu@gmail.com",{"name":52,"role":47,"phone":53,"phoneExt":49,"email":54},"Sevil Cankaya, MD","+90 505 866 34 09","sevilsaltek82@gmail.com",[56],{"facility":57,"status":49,"city":58,"state":49,"zip":59,"country":60,"countryCode":49,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital","Istanbul","34785","Turkey (Türkiye)",{"type":62,"coordinates":63},"Point",[64,65],28.94966,41.01384,{"lat":65,"lon":64},[68,69,70],{"name":46,"role":47,"phone":48,"phoneExt":49,"email":50},{"name":52,"role":47,"phone":53,"phoneExt":49,"email":54},{"name":46,"role":43,"phone":49,"phoneExt":49,"email":49},{"type":72,"investigatorFullName":49,"investigatorTitle":49,"investigatorAffiliation":49,"oldNameTitle":49,"oldOrganization":49},"SPONSOR","100631101","comparison-of-oral-dydrogesterone-and-vaginal-progesterone-in-menopausal-hormone-therapy-100631101",false,"NCT07496294","Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy","Comparison of Oral Dydrogesterone and Vaginal Micronized Progesterone Regimens Combined With Transdermal Estradiol in Menopausal Hormone Therapy: A Prospective Randomized Controlled Trial","PRO-MHT","Inclusion Criteria:\n\n* Women aged 45-60 years\n* Postmenopausal status (absence of menstruation for ≥12 months)\n* Intact uterus\n* Presence of menopausal symptoms requiring menopausal hormone therapy\n* Willingness to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Unexplained vaginal bleeding\n* History of breast cancer or endometrial cancer\n* Known hypersensitivity to study medications\n* History of thromboembolic disease (e.g., deep vein thrombosis or pulmonary embolism)\n* Severe liver disease\n* Uncontrolled hypertension\n* Any condition that, in the opinion of the investigator, makes participation inappropriate","FEMALE","45 Years","60 Years",{"count":85,"type":86},200,"ESTIMATED","INTERVENTIONAL",[89],"NA","Menopause is a natural stage in a woman's life that can be associated with symptoms such as hot flashes, night sweats, sleep problems, and vaginal dryness. Menopausal hormone therapy is commonly used to relieve these symptoms. In women with an intact uterus, progesterone must be used together with estrogen to protect the lining of the uterus.\n\nThe purpose of this study is to compare two commonly used progesterone treatment methods in women receiving menopausal hormone therapy. All participants will use transdermal estradiol gel, and they will be randomly assigned to receive either oral dydrogesterone or vaginal micronized progesterone.\n\nThis prospective randomized controlled study will evaluate the effects of these treatments on endometrial thickness, menopausal symptoms, vaginal health parameters, bleeding patterns, and quality of life over a 12-month follow-up period.\n\nThe results of this study may help determine the most appropriate progesterone regimen for women undergoing menopausal hormone therapy.",[92,93,94,95],"Menopausal Women","Menopausal Symptom Relief","Hormone Therapy","Menopausal Hormone Therapy",[97,98,99,35,100,101,102,103],"Menopausal hormone therapy","Dydrogesterone","Micronized progesterone","Progesterone route of administration","Endometrial thickness","Postmenopausal women","Randomized controlled trial","NOT_YET_RECRUITING","2026-03-23",{"date":107,"type":108},"2026-03-27","ACTUAL",{"date":110,"type":86},"2026-04",{"date":112,"type":86},"2027-10",{"name":5,"class":6},1]